Future optimization efforts may include incorporating PD-1 or CTLA-4 blockade as combinational therapies, exploring additional preclinical models such as orthotopic tumor models, and refining degrader design to enhance in vivo performance and translational potential. This evidence concerns the gene CTLA4 and neoplasm.